Bengaluru: Biocon Limited today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board of Directors.As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the Company’s ability to operate at scale and compete effectively in global markets.Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited.This leadership transition is part of the full integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies.Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said: “Biocon has consistently grownby anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise.Also Read:Biocon Secures USFDA Nod for Generic Liraglutide Prefilled Pens for DiabetesShreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint. Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion. As the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”Speaking on Siddharth Mittal’s contributions, Mazumdar-Shaw added: “I would like to thank Siddharth for his tremendous contributions to Biocon. Since joining in 2013, he has served with distinction as Chief Financial Officer and later as CEO & Managing Director, playing a pivotal role in shaping the company’s growth trajectory. He will now transition to another leadership role within the Biocon Group.”Shreehas Tambe, CEO & Managing Director, Biocon Limited, said: “It is an honor and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company. Biocon is among the few organizations that have transformedaccess to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs. As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth. I am deeply grateful to our visionary Chairperson Kiran Mazumdar-Shaw and the Board of Directors for the trust and confidenceplaced in me and look forward to building on Biocon’s strong legacy to make a meaningful difference for patients worldwide.”Also Read: Biocon Gets USFDA Nod for gSaxenda, Enters US GLP-1 Weight Loss MarketShreehas Tambe joined Biocon nearly three decades ago as a management trainee and, through successive leadership roles, has played a pivotal role in scaling multiple businesses globally. During his tenure as the CEO and Managing Director of Biocon Biologics, the company has become one of the world’s Top 5 biosimilar companies by revenue with a valuation of USD 5.5 billion in 2025. He led the transformational acquisition of Viatris’ biosimilars business and oversaw its rapid consolidation, creating a fully integrated, lab-to-patient, global biologics enterprise.Previously, Shreehas served as Chief Operating Officer and later Deputy CEO of Biocon Biologics, driving enterprise-wide operations and global growth. Earlier at Biocon, he led the worldwide expansion of the insulins business, including the establishment of Asia’s largest integrated insulins facility in Malaysia. Shree has started his career in Research & Development and is an inventor on 61 patents, reflecting his commitment to advancing innovation.As the first CEO & Managing Director of the combined business, he will be responsible for strengthening Biocon’s position as a global biopharma leader that is addressing the world’s most pressing healthcare needs by advancing a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP‑1s).Shreehas holds a Master’s degree in Bioprocess Technology from ICT (UDCT), University of Mumbai, and has received multiple industry recognitions, including the ET Edge India’s Impactful CEO Award in 2025, the BW Pharma World Pharma Leadership Award along with the Times Now Most Promising Business Leaders of Asia Award in 2026.He has represented India’s biopharmaceutical sector at leading global forums and worked closely with policymakers on initiatives such as Production Linked Incentive (PLI) and Promotion of Research and Innovation in Pharma MedTech Sector (PRIP)